RYTM Since 2017 Annualized Return and Average Annual Return

RYTM Average Annual Return Chart Since 2017
Growth of $10,000.00
Without Dividends Reinvested Into RYTM

Also see:
• RYTM stock yearly return 2018
• RYTM stock yearly return 2019
• RYTM stock yearly return 2020
• RYTM stock yearly return 2021
• RYTM stock yearly return 2022
• RYTM stock yearly return 2023
• RYTM stock yearly return 2024
• RYTM stock yearly return 2025
• RYTM YTD return
Average Annual Return Benchmarks
Compare RYTM average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
RYTM Share Performance
RYTM Average Annual Return Table Since 2017
Start date: 10/10/2017
End date: 05/08/2026
Start price/share: $26.01
End price/share: $94.17
Dividends collected/share: $0.00
Total return: 262.05%
RYTM Average Annual Return: 16.18%
Starting investment: $10,000.00
Ending investment: $36,214.35
Years: 8.58


RYTM average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE. IMCIVREE is a precision medicine approved by the FDA for chronic weight management in adults and children aged six and older with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiencies, or Bardet-Biedl syndrome (BBS). The company is also evaluating setmelanotide in Phase II and III trials for treating obesity linked to various MC4R pathway gene variants. The RYTM average annual return since 2017 is shown above.

The Average Annual Return on the RYTM average annual return since 2017 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether RYTM average annual return since 2017 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the RYTM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
RYTM Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree RYTM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Rhythm Pharmaceuticals (RYTM) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

RZLT Average Annual Return
SABS Average Annual Return
SANA Average Annual Return
SBFM Average Annual Return
SCYX Average Annual Return
SDGR Average Annual Return
SEER Average Annual Return
SEM Average Annual Return
SENS Average Annual Return
SERA Average Annual Return
More Healthcare companies »
 

RYTM Average Annual Return Since 2017 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.